BioSpace News Archive

Creative Medical Technology Holdings, Inc. today announced progress in developing a reproducible clinical grade product of ImmCelz®. Multiple clinical experiments were performed in which the ImmCelz® product was produced in less than 72 hours, utilizing the Company’s cell-free supercharging solution.

NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced it will host the second of four virtual R&D events on Wednesday, April 27, 2022, from 11:00 am – 12:30 pm ET.

Reveles Clinical Services (Reveles), a purposeful, decentralized clinical trial (DCT) management company, today announced the availability of industry-leading technology to digitize the clinical trial process for patients, sites and sponsors.

enlightenVue™, Inc. announced today the initial closing of a $1 million Series B financing to expand the application of its FDA-cleared, surgiVue™ single-use micro-endoscope platform.

Engooden Health, a company redefining chronic disease management, today announced a partnership with HAPevolve, a subsidiary of The Hospital and Healthsystem Association of Pennsylvania (HAP).

Moving beyond the proven tech and best-selling success of the i700 intraoral scanner, MEDIT announces the release of the i700 wireless – newly designed as a portable wand with the same speed, accuracy, and lightness.

Global health services company Cigna Corporation (NYSE:CI) announced today that Brian Evanko, executive vice president and chief financial officer, will present at the BofA Securities 2022 Healthcare Conference on May 11, 2022 in Las Vegas, NV.

On April 1, Dragon Boat Pharmaceutical announced that its self-developed anti-CLDN18.2 antibody injection (BC008) had obtained the implied approval for clinical trials from China’s National Medical Products Administration, and will be used for the clinical trials in the treatment of CLDN18.2-positive advanced malignant solid tumors.

The global medical imaging equipment market is estimated to expand growth at a CAGR of 5.4% from 2021 to 2028 and to reach valuation of US$ 50.3 Bn by the end of 2030.

Hemophilia, a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor, factor VIII.